Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome
A Phase II Multicentre Multinational Prospective Randomised Double-blind Placebo-controlled Study Assessing the Efficacy and Safety of a Single Application of Three Doses of Dysport® in Patients With Upper Back Myofascial Pain Syndrome
Sponsor: Ipsen
Listed as NCT00134810, this PHASE2 trial focuses on Myofascial Pain Syndromes and remains completed. Sponsored by Ipsen, it has been updated 9 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Aug 2019 — Dec 2019 [monthly]
Completed PHASE2
-
Feb 2019 — Aug 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Mar 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Badalona, Spain , Barcelona, Spain , Bochum, Germany , Brno, Czechia , Elblag, Poland , Frankfurt am Main, Germany , Göppingen, Germany , Jena, Germany , Kiel, Germany , Lisbon, Portugal and 10 more locations